Nilotinib Viatris (Nilotinib)

Nilotinib selectively binds to the ATP‑binding pocket of the BCR‑ABL fusion protein, inhibiting its tyrosine‑kinase activity. This blocks downstream signaling pathways that promote leukemic cell proliferation and survival, leading to apoptosis of malignant cells while sparing most normal tissues.

The dosing regimen for Nilotinib Viatris is determined by the prescribing physician based on the patient’s disease phase, response, and tolerability. Healthcare professionals adjust the dose according to clinical guidelines and individual patient factors.

Safety data for nilotinib in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit outweighs the risk, and breastfeeding is not recommended while on therapy. Consultation with a specialist is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor offering higher potency and selectivity compared with first‑generation agents like imatinib. It may achieve faster and deeper molecular responses, but it also carries a distinct safety profile, including a higher risk of QT prolongation, requiring individualized assessment.

Nilotinib Viatris tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid environments such as bathrooms.

The medication is taken orally, usually twice daily on an empty stomach (at least one hour before or two hours after a meal). Patients should swallow the tablets whole with water and follow the prescriber’s instructions regarding timing and any required dietary restrictions.

Serious risks include QT interval prolongation, which can lead to life‑threatening arrhythmias, severe hepatotoxicity, pancreatitis, and profound neutropenia or thrombocytopenia. Patients should be monitored regularly for cardiac, hepatic, and hematologic parameters, and any concerning symptoms should be reported promptly.

Nilotinib is contraindicated in patients with a known hypersensitivity to nilotinib or any of its excipients, and in individuals with a history of prolonged QT interval or uncontrolled cardiac arrhythmias. It should also be avoided in patients taking strong CYP3A4 inhibitors without appropriate dose adjustments.